Bloomberg Anywhere Login


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last kr11.00 SEK
Change Today +0.45 / 4.27%
Volume 84.0K
ACTI On Other Exchanges
As of 7:56 AM 07/29/15 All times are local (Market data is delayed by at least 15 minutes).

active biotech ab (ACTI) Snapshot

Previous Close
Day High
Day Low
52 Week High
08/14/14 - kr33.60
52 Week Low
06/5/15 - kr8.45
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield
Current Stock Chart for ACTIVE BIOTECH AB (ACTI)

Related News

No related news articles were found.

active biotech ab (ACTI) Related Businessweek News

No Related Businessweek News Found

active biotech ab (ACTI) Details

Active Biotech AB (publ) develops drugs for the treatment of neurodegenerative diseases and cancer. The company has two projects in clinical development, such as laquinimod and tasquinimod. The Laquinimod project is a novel immunomodulatory compound for the treatment of neurodegenerative diseases; and the Tasquinimod project is an immunomodulatory, anti-metastatic substance for the treatment of prostate cancer. The company is also developing Paquinimod, an oral immunomodulatory compound for the treatment of systemic sclerosis; and RhuDex, an orally active compound for the treatment of autoimmune diseases. Its preclinical project product is ISI–Inhibition of S100 Interactions for producing patentable chemical compounds that interact with one of the quinoline compounds’ target molecules. Active Biotech AB (publ) is headquartered in Lund, Sweden.

56 Employees
Last Reported Date: 04/23/15

active biotech ab (ACTI) Top Compensated Officers

Chief Executive Officer and President
Total Annual Compensation: kr5.0M
Compensation as of Fiscal Year 2013.

active biotech ab (ACTI) Key Developments

Teva Pharmaceutical Industries Limited and Active Biotech Announce the Completion of Patient Enrollment in Laquinimod Phase III CONCERTO Trial

Teva Pharmaceutical Industries Ltd. and Active Biotech announced that the patient enrollment for the pivotal Phase III CONCERTO trial has been finalized, as well as a planned sample size re-assessment analysis of the study. CONCERTO, the third Phase III trial of laquinimod in patients with relapsing-remitting multiple sclerosis (RRMS), is designed to evaluate the safety and efficacy of laquinimod (0.6mg or 1.2mg/day) with a primary endpoint of time to Confirmed Disability Progression (CDP), as measured by the Expanded Disability Status Scale (EDSS). The sample size reassessment was included as part of the protocol to confirm that the original assumptions are in line with the study and that the sample size is adequate. Based on recent agreement with FDA, under a Special Protocol Assessment (SPA) agreement, study completion will occur when either 260 events are reached or all patients complete 24 months of study treatment (whichever occurs first). CONCERTO study results are expected to be available toward mid-2017.

Active Biotech Announces Redundancies of 47 of its Employees

Active Biotech announced that the company has made a notification of planned redundancies of 47 of its employees, which means a significant down-sizing of the operations. A notification of planned redundancies has been submitted to the local authorities ("Arbetsförmedlingen") for 47 employees out of 56. Active Biotech has also called for negotiations with the trade unions and contacts have been established with organizations such as the Swedish Employment Security Council regarding various support measures for the employees. The planned organizational change is estimated to be fully implemented as of 1 January, 2016. Active Biotech's planned organizational adjustment leads to substantially reduced operating costs. The operating costs are expected to decrease to approximately SEK 50 Million per year, from 2016.

Teva Pharmaceutical Industries Ltd. and Active Biotech Announce First Patient Enrolled in Phase II Study Evaluating Laquinimod for Primary Progressive MS

Teva Pharmaceutical Industries Ltd. and Active Biotech announced the first patient has been enrolled in the study ARandomized Placebo-controlled Trial Evaluating Laquinimod in PPMS, Gauging Gradations In MRI and Clinical Outcomes, a Phase II study to evaluate laquinimod, an investigational, oral, immune modulator, for the treatment of primary progressive multiple sclerosis. Currently there are no approved treatments for PPMS, representing a condition with a high unmet need. PPMS affects approximately 15% of all MS patients and is characterized by the worsening of neurologic function without distinct relapses. Unlike patients with relapsing-remitting MS, those with PPMS tend to have more lesions in the spinal cord than in the brain and these brain lesions usually contain fewer inflammatory cells. In addition, all studies evaluating RRMS treatments in patients with PPMS have failed to prove effective for this condition. ARPEGGIO is a multinational, multicenter, randomized, double-blind, parallel-group, placebo-controlled study of once-daily, oral laquinimod in patients with PPMS. The study’s primary endpoint is percent brain volume change through MRI analysis. The trial will enroll approximately 375 patients in the U.S., Canada, and Europe. Additional details on the study design will be presented at the AAN Annual Meeting in Washington, D.C. on April 23, 2015 during Poster Session 7.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
ACTI:SS kr11.00 SEK +0.45

ACTI Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for ACTI.
View Industry Companies

Industry Analysis


Industry Average

Valuation ACTI Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 84.7x
Price/Book 2.7x
Price/Cash Flow NM Not Meaningful
TEV/Sales 40.8x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact ACTIVE BIOTECH AB, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at